Centauri Therapeutics LIMITED

Centauri Therapeutics LIMITED is a privately-owned biotech company that develops novel immunotherapeutics to treat life-threatening diseases. It has developed an immunotherapeutic platform called Alphamers that redirects pre-existing natural antibodies to target specific diseases with applications for cancer and infectious diseases.

Through past federal contract sub-awards from prime contractor Trustees of Boston University, Centauri Therapeutics LIMITED has provided research and development services for its Alphamer platform, which comprises a targeting domain that binds to bacteria, an antibody-recruiting effector domain that recruits pre-existing natural anti-Gal antibodies, and proprietary linker technology. The company's lead program, CTL-ABX01, targets drug-sensitive and multi-drug resistant Gram-negative bacteria, including clinically relevant strains of Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The Alphamer platform combines the power of the immune system with direct antibacterial action in one drug.

Through past federal grant sub-awards from prime grantee Trustees of Boston University, Centauri Therapeutics LIMITED has also provided research and development services for its Alphamer platform, specifically aiming to better understand the immune-mediated translation and efficacy of the Alphamer in vivo by executing appropriate disease models to predict an efficacious dose for human use. The company's goal is to select lead compounds for clinical candidate selection studies, complete pre-IND-enabling studies, and conduct a first-in-human study for its Alphamer platform.